Letters to the Editor
Biosimilars naming and prescribing policy in Australia
Submitted: 31 October 2013; Revised: 6 November 2013; Accepted: 11 November 2013; Published online first: 25 November 2013 To the Editor: I wanted to bring to your attention the following… Read More »
WHO leadership in public safety on biosimilars to be commended
Abstract: As a practicing endocrinologist and Chairman of the Alliance for Safe Biologic Medicines, I am writing to commend the World Health Organization for its attention to and upcoming action… Read More »
Critical immunogenicity differences will be obscured by a common INN for biosimilars
Abstract: Information about variable immunogenicity arising from formulation differences between competing biosimilars is critical for informed judgments by prescribing physicians. Use of a common INN for biosimilars will obfuscate such… Read More »
Legislative efforts to limit prescription information sharing between patients and healthcare providers represent a serious threat to the health and safety of the American nation
Abstract: Legislation in support of pharmacist notification to patients and providers of substitution of an interchangeable biologic for the originator biologic was recently vetoed in California. Automatic substitution of approved… Read More »
Challenges to generic medicines utilization in Yemeni healthcare system
Author(s): 1 Saleh Karamah AL-Tamimi, BPharm, MPharm (ClinPharm), 2 Mohamed Azmi Ahmad Hassali, PhD, 3 Alian A Alrasheedy, BPharm(Hons), MPharm(Clin), BCPS
Page: 63-4
Abstract: Generic medicines are promoted in many countries as an essential part of the healthcare system. However, in Yemen, there are many challenges to the utilisation of generic medicines. Currently,… Read More »
Austria increases dialogue in order to involve physicians more with biosimilars
Abstract: Comment on the GaBI Journal article titled The potential for doctors to contribute to biosimilar guidelines [1] and the GaBI Online article titled Dialogue needed to build confidence in… Read More »
The ethics of biosimilars
Abstract: Comment on the Letters to the Editor by Dr Carlo Petrini: A bioethicist’s view of the use of biosimilars, published in GaBI Journal, 2012, issue 3-4. Submitted: 9 November 2012; Revised: 12… Read More »
A clinician’s view of the ethics of the use of biosimilars
Abstract: Comment on the Letters to the Editor by Dr Carlo Petrini: A bioethicist’s view of the use of biosimilars Submitted: 8 October 2012; Revised: 9 October 2012; Accepted: 9 October 2012;… Read More »
A bioethicist’s view of the use of biosimilars
Abstract: In recognition of the many ethically sensitive issues raised by the production and use of biosimilar medicinal products, the author imagines having to answer the non-multiple choice question ‘From… Read More »